Savara (SVRA) closed at $4.48 on November 17, 2026, up 0.3% from the previous close, on volume of 3,266,441 shares (30-day average 2,610,436).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 13, 2026 | Call Butterfly | 18-Dec-265 : 7[2x] : 9 C | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Savara (SVRA) Receives a Buy from Guggenheim
TipRanks (Mon, 16-Nov 8:17 AM ET)
Savara Announces New Employment Inducement Grant
Business Wire (Thu, 12-Nov 4:05 PM ET)
Business Wire (Wed, 21-Oct 1:10 PM ET)
Business Wire (Mon, 12-Oct 4:05 PM ET)
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara trades on the NASDAQ stock market under the symbol SVRA.
As of November 18, 2026, SVRA stock price climbed to $4.72 with 5,028,131 million shares trading.
SVRA has a beta of 1.09, meaning it tends to be more sensitive to market movements. SVRA has a correlation of 0.07 to the broad based SPY ETF.
SVRA has a market cap of $1.04 billion. This is considered a Small Cap stock.
Last quarter Savara reported $0 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-1 million and met earnings estimates .
In the last 3 years, SVRA traded as high as $7.01 and as low as $1.89.
The top ETF exchange traded funds that SVRA belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
SVRA has outperformed the market in the last year with a price return of +12.4% while the SPY ETF gained +10.8%. However, in the short term, SVRA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -12.1% vs -5.3% return in SPY. But in the last 2 weeks, SVRA shares have fared better than the market returning -0.6% compared to SPY -3.2%.
SVRA support price is $4.27 and resistance is $4.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SVRA shares will trade within this expected range on the day.